Liver transplantation performed in a SARS‐CoV‐2 positive hospitalized recipient using a SARS‐CoV‐2 infected donor. Issue 7 (17th March 2021)

• Record Type: Journal Article
• Authors: Manzia, Tommaso Maria; Gazia, Carlo; Lenci, Ilaria; Angelico, Roberta; Toti, Luca; Monaco, Andrea; Anselmo, Alessandro; Baiocchi, Leonardo; Grossi, Paolo; Tisone, Giuseppe
• Is Part Of: American journal of transplantation. Volume 21:Issue 7(2021)
• Page Start: 2600
• Page End: 2604
• Publication Date: 2021-03-17
• Subjects: clinical research/practice -- donors and donation: extended criteria -- infection and infectious agents ‐ viral -- infectious disease -- liver transplantation/hepatology -- organ procurement and allocation; Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ajt.16548
• Languages: English
• ISSNs: 1600-6135

Abstract

Abstract : The coronavirus disease 2019 (COVID‐19) is a novel infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). COVID‐19 currently affected more than 108 million people worldwide with a fatality rate of 2.2%. Herein, we report the first case of liver transplantation (LT) performed with a liver procured from a SARS‐CoV‐2 positive donor. The recipient was a 35‐year‐old SARS‐CoV‐2 positive female patient affected by severe end‐stage HBV‐HDV‐related liver disease (model of end‐stage liver disease = 32) who had neutralizing SARS‐CoV‐2 antibodies (titers 1:320) at time of LT. The LT was successful, and the graft is functioning two months after surgery. The recipient cleared the SARS‐CoV‐2 infection 1 month after LT. The current case shows that the prompt use of SARS‐CoV‐2 infected liver donors offers an invaluable life‐saving opportunity for SARS‐CoV‐2 positive wait‐listed patients who developed neutralizing SARS‐CoV‐2 antibodies. Abstract : Considering the organ shortage and the current COVID‐19 pandemic, livers from SARS‐CoV‐2–positive donors may be an option for transplant candidates with a history of SARS‐CoV‐2 infection who have developed neutralizing antibodies.